✦ LIBER ✦

3 years of adefovir and lamivudine combination therapy minimizes the risk of genotypic resistance to ADV in lamivudine resistant patients

✍ Scribed by P. Lampertico; M. Viganò; E. Manenti; M. Iavarone; G. Lunghi; E. Del Ninno; M. Colombo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[57] 3 YEARS OF ADEFOVIR AND LAMIVUDINE

✍ P. Lampertico; M. Vigano; E. Manenti; M. Tavarone; G. Lunghi; E. Del Ninno; M. C 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Low risk of adefovir resistance in lamiv

✍ Hiromi Yatsuji; Fumitaka Suzuki; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Y 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Low Resistance to Adefovir Combined With

✍ Pietro Lampertico; Mauro Viganò; Elena Manenti; Massimo Iavarone; Erwin Sablon; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 538 KB

Four-year study of lamivudine and adefov

✍ J. Inoue; Y. Ueno; Y. Wakui; H. Niitsuma; K. Fukushima; Y. Yamagiwa; M. Shiina; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB

696 ADD ON ADEFOVIR PREVENTS THE EMERGEN

✍ P. Lampertico; M. Vigano; E. Manenti; M. Iavarone; M. Colombo 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

High risk of renal impairment during lon

✍ M. Viganò; P. Lampertico; M. Iavarone; G.E. Tontini; F. Facchetti; M. Colombo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 72 KB